You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 67 No. 7, July 2010 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  This Month in Archives of Neurology
 •Online Features
 This Article
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

This Month in Archives of Neurology

Arch Neurol. 2010;67(7):793-794. doi:10.1001/archneurol.2010.134

When Does Parkinson Disease Start?



Savica and colleagues (SEE ARTICLE) review the convincing evidence that the Parkinson disease neurodegenerative process begins many years before the onset of motor manifestations. Initial estimates based on nigral neuropathology or striatal dopamine imaging suggested a 5- to 6-year preclinical period. Epidemiologic studies of nonmotor manifestations such as constipation, anxiety disorders, rapid eye movement sleep behavior disorder, or anemia suggested that the preclinical period extends at least 20 years before the motor manifestations. Olfactory impairment and depression may also precede the onset of motor manifestations; however, the lag time may be shorter. Recognition of a nonmotor preclinical phase spanning 20 or more years should guide the search for predictive biomarkers and the identification of risk or protective factors for Parkinson disease.


Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Latov et al (SEE ARTICLE) investigate the timing, course, and clinical characteristics of the response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Their data suggest that treatment with 2 doses of immune globulin intravenous, 10% caprylate/chromatography purified, given every 3 weeks may be required for initial improvement, and continued maintenance therapy may be necessary to achieve a maximal therapeutic response.


Figure 05002FA
Responders who reached maximal improvement. Cumulative number of responders in immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C) and placebo groups reaching maximal adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) score improvement.



Serum Vitamin D and the Risk of Parkinson Disease

Knekt and colleagues (SEE ARTICLE) point out that low vitamin D status has been suggested to be related to Parkinson disease risk. They have investigated whether serum vitamin D level predicts the risk of Parkinson disease. Individuals with higher serum vitamin D concentrations showed a reduced risk of Parkinson disease. Their results are consistent with the suggestion that high vitamin D status provides protection against Parkinson disease. Editorial perspective is provided by Marian L. Evatt, MD, MS. (SEE ARTICLE)


Imaging Cortical Lesions in Multiple Sclerosis With Ultra–High-Field MRI

Pitt et al (SEE ARTICLE) indicate that conventional magnetic resonance imaging has a low sensitivity for cortical demyelination, making it difficult to establish the effect of cortical pathology on the disease course. Ultra–high-field (7-T) magnetic resonance imaging with intrinsically high signal to noise ratio, spatial resolution, and image contrast can visualize previously unattainable morphological details. They report that 3-dimensional, T2*-weighted gradient-echo and white matter–attenuated turbo-field-echo sequences at 7-T field strength detect most cortical lesions in postmortem multiple sclerosis tissue. This study indicates the potential of T2*-weighted gradient-echo and white matter–attenuated turbo-field-echo imaging at ultra–high-field magnetic resonance imaging for cortical lesion detection in patients with multiple sclerosis.


Dietary Antioxidants and Long-term Risk of Dementia

Devore and colleagues (SEE ARTICLE) have studied the consumption of major dietary antioxidants in relation to long-term risk of dementia. They conclude that higher intake of foods rich in vitamin E may modestly reduce long-term risk of dementia and Alzheimer disease.


Neurobehavioral Features in Frontotemporal Dementia With Amyotrophic Lateral Sclerosis

Lillo et al (SEE ARTICLE) compare the clinical features at presentation in patients with behavioral variant frontotemporal dementia (FTD) who develop amyotrophic lateral sclerosis (ALS) vs those who do not develop ALS. Of note, they find that delusions were particularly common in patients destined to develop FTD/ALS. The occurrence of delusions in the context of behavioral variant FTD should lead to an early search for ALS features.


Renal Failure and Posterior Reversible Encephalopathy Syndrome in Patients With Thrombotic Thrombocytopenic Purpura

Burrus and colleagues (SEE ARTICLE) find that knowledge is limited related to the neurologic manifestations associated with thrombotic thrombocytopenic purpura (TTP). Of patients who had acute abnormalities on brain magnetic resonance imaging, 13 (48%) were found to have posterior reversible encephalopathy (PRES). The only variable highly associated with PRES on neuroimaging was the glomerular filtration rate (P = .02). The occurrence of PRES in patients with acute TTP is associated with worse renal function.


Prediction of Alzheimer Disease in Elderly Persons

Reitz et al (SEE ARTICLE) aim to develop a simple summary risk score for the prediction of Alzheimer disease in elderly persons based on their vascular risk profiles. Risk factors that contributed to the risk score were age, sex, education, ethnic group, apolipoprotein E {varepsilon}4 genotype, history of diabetes, hypertension, or smoking, high-density lipoprotein levels, and waist to hip ratio. The resulting risk score predicted dementia well.


Periventricular Venous Infarction and Arterial Presumed Perinatal Ischemic Stroke

Kirton and colleagues (SEE ARTICLE) indicate that periventricular venous infarction (PVI) has emerged as an important and unique cause of presumed perinatal ischemic stroke (PPIS). They hypothesize that clinical presentations and risk factor profiles differ between PVI and arterial PPIS. They find that PPIS diagnosis is often delayed, and the association of acute perinatal risk factors with arterial PPIS compared with PVI supports distinct timing of these diseases. Prospective, case-control risk factor studies of PPIS subtypes will be required to develop prevention strategies.


Mitochondrial Respiratory Chain Dysfunction in Amyotrophic Lateral Sclerosis

Crugnola et al (SEE ARTICLE) submit that, although defects of the mitochondrial respiratory chain have been described in several patients with amyotropic lateral sclerosis (ALS), their pathogenic significance is unclear. Their data confirm that the histochemical finding of cytochrome c oxidase–negative fibers is common in the skeletal muscle of patients with sporadic ALS. In 7 patients, the oxidative defect was severe enough to support the hypothesis that mitochondrial dysfunction must play a role in the pathogenesis of the disease.


Telephone Assessment of Cognitive Function in the Late-Onset Alzheimer’s Disease Family Study

Wilson and colleagues (SEE ARTICLE) find that administration of cognitive test batteries by telephone has been shown to be a valid and cost-effective means of assessing cognition but it remains relatively uncommon in epidemiological research. They report that assessment of cognition by telephone has little effect on performance and provides operational flexibility and a means of reducing costs and missing data.


Autobiographical Memory Task in Assessing Dementia

Dreyfus et al (SEE ARTICLE) appraise the relationship of a task assessing memory for recent autobiographical events and those of 2 commonly used brief memory tasks with the results of a clinical assessment for dementia. The autobiographical recall task and each of the other brief clinical measures correlate significantly with the Clinical Dementia Rating sum of boxes (P < .001). The autobiographical recall task has a significantly higher correlation (P < .001) with the Clinical Dementia Rating sum of boxes than the 2 commonly used clinical memory measures.


Elevation of β-Amyloid 1-42 Autoantibodies in the Blood of Amnestic Patients With Mild Cognitive Impairment

Storace and colleagues (SEE ARTICLE) report the average plasma levels of β-amyloid 1-42 plasma autoantibodies of patients with mild cognitive impairment who progress to having Alzheimer disease, but not that of the stable cases, is significantly higher than in cognitively normal controls (P < .001). The evaluation of β-amyloid 1-42 autoantibodies, after dissociation of the complexes, is a simple and inexpensive method that may be used to predict the occurrence of Alzheimer disease.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2010 American Medical Association. All Rights Reserved.